Secondary Failure of Tocilizumab in Treating Elderly-Onset Rheumatoid Arthritis With Systemic Symptoms Complicated by Diverticulum Perforation

Soshi Takagi 1, Yumi Naito 2, Chiaki Sano 3, Ryuichi Ohta 2

Abstract

The treatment of rheumatoid arthritis (RA) has advanced from the use of steroids to disease-modifying anti-rheumatic drugs (DMARDs) and biologics such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) inhibitors. Historically, steroids have been the mainstream treatment in the clinical treatment of RA; however, the development of DMARDs has changed the RA treatment structure. In addition, biologics can alleviate RA symptoms. This case report describes the secondary failure of tocilizumab in treating RA with fatigue symptoms. Treatment with tocilizumab decreases C-reactive protein (CRP) levels, which may make detecting RA exacerbation difficult; therefore, obtaining the patient’s precise history and thorough physical examinations are necessary. This case demonstrates the complexity of treating elderly-onset RA and reports practical methods for effective treatment.

Introduction

The treatment of rheumatoid arthritis (RA) has advanced from the use of steroids to disease-modifying anti-rheumatic drugs (DMARDs) and biologics such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) inhibitors [1,2]. Steroids have been the mainstream treatment in the clinical history of RA therapy; however, the development of DMARDs has changed the RA treatment structure [3]. DMARDs, such as methotrexate (MTX), have now become the mainstream treatment for RA [4]. In addition, biologics are also used to alleviate RA symptoms [4]. The introduction of DMARDs and biologics has improved patients’ quality of life with RA [1,2]. Therefore, with the increasing advances in the treatment of RA, these must be updated in rural hospitals.

The increase in the use of biologics could confuse the treatment of RA because biologics can influence changes in the biomarkers of inflammation. For instance, anti-IL 6 inhibitors can induce a drastic decrease in the amount of C-reactive protein (CRP) in the serum, which is a clinical indicator of inflammation in RA [1,2]. Moreover, the continuous use of biologics may cause secondary failure due to the production of antibodies against the biologics. The human body can produce antibodies against biologics, rendering biologics ineffective in treating patients with RA [1,2]. Additionally, the secondary failure rate may increase in patients with RA who do not use DMARDs. Therefore, CRP should not be used to detect disease exacerbation in RA patients using anti-IL 6 inhibitors [4]. Here, we report the case of an older woman diagnosed with elderly-onset RA (EORA) treated with tocilizumab, with chief complaints of fatigue and systemic pain. In this case, we could not use CRP to detect RA exacerbation, which necessitated obtaining a precise medical history and thorough physical examination. Herein, we discuss the complexity of treating EORA and report practical methods for effective treatment.

Case Presentation

A 72-year-old woman presented to our hospital with chest tightness, dizziness, and abdominal fullness. She had visited our ER with the same symptoms five days prior. At that time, the patient was diagnosed with benign paroxysmal positional vertigo (BPPV). Four days after the BPPV diagnosis, she visited our otorhinolaryngology department, and the doctor followed up on her symptoms. Her medical history included EORA, osteoporosis, spinal canal stenosis, cataracts, and vertebral compression fracture. Her medication history included tacrolimus, trimethoprim-sulfamethoxazole, tocilizumab, esomeprazole, and risedronate. For her EORA, she had been using prednisolone for three years until six months prior, when prednisolone was switched to tacrolimus and tocilizumab. She had last used tocilizumab one week before the visit.

Her vital signs were as follows: blood pressure of 148/78 mmHg, heart rate of 81/min, body temperature of
36.6°C, respiratory rate of 18/min, and oxygen saturation (SpO₂) of 97% on room air. Her consciousness was clear. Physical examination revealed right lower abdominal tenderness upon percussion. Laboratory tests revealed normal white blood cell count and C-reactive protein levels (Table 1).

| Marker                        | Level  | Reference          |
|-------------------------------|--------|--------------------|
| White blood cells             | 3.7    | 3.5–9.1 × 10³/µL   |
| Neutrophils                   | 55.2   | 44.0–72.0%         |
| Lymphocytes                   | 35.3   | 18.0–59.0%         |
| Monocytes                     | 7.8    | 0.0–12.0%          |
| Eosinophils                   | 1.3    | 0.0–10.0%          |
| Basophils                     | 0.4    | 0.0–3.0%           |
| Red blood cells               | 3.70   | 3.76–5.50 × 10⁶/µL |
| Hemoglobin                    | 12.2   | 11.3–15.2 g/dL     |
| Hematocrit                    | 35.9   | 33.4–44.9%         |
| Mean corpuscular volume       | 97     | 79.0–100.0 fl      |
| Platelets                     | 18.3   | 13.0–36.9 × 10⁴/µL |
| Erythrocyte sedimentation rate| 10     | 2–10 mm/hour       |
| Total protein                 | 6.7    | 6.5–8.3 g/dL       |
| Albumin                       | 3.4    | 3.8–5.3 g/dL       |
| Total bilirubin               | 0.8    | 0.2–1.2 mg/dL      |
| Aspartate aminotransferase    | 53     | 8–38 IU/L          |
| Alanine aminotransferase      | 20     | 4–43 IU/L          |
| Alkaline phosphatase          | 156    | 106–322 U/L        |
| γ-Glutamyl transpeptidase     | 269    | <48 IU/L           |
| Lactate dehydrogenase         | 161    | 121–245 U/L        |
| Blood urea nitrogen           | 18.9   | 8–20 mg/dL         |
| Creatinine                    | 0.71   | 0.40–1.10 mg/dL    |
| Serum Na                      | 137    | 135–150 mEq/L      |
| Serum K                       | 3.9    | 3.5–5.3 mEq/L      |
| Serum Cl                      | 102    | 98–110 mEq/L       |
| CK                            | 124    | 56–244 U/L         |
| CRP                           | 0.04   | <0.30 mg/dL        |
| TSH                           | 0.34   | 0.35–4.9 µU/mL     |
| Free T4                       | 1      | 0.70–1.48 ng/dL    |
| HBs antigen                   | 0.0    | IU/mL              |
| HBs antibody                  | 0.67   | mIU/mL             |
| Hbc antibody                  | 0.00   | S/CO               |
| HCV antibody                  | 0.00   | S/CO               |
| Syphilis treponema antibody   | 0.00   | S/CO               |
| SARS-CoV-2 antigen            | Negative |
| Test                          | Value   | Reference Range   |
|-------------------------------|---------|-------------------|
| anti-nuclear antibody         | 320     | <40               |
| homogeneous                   | 320     | <40               |
| C3                            | 55      | 86–164 mg/dl      |
| C4                            | 5       | 17–45 mg/dl       |
| MPO-ANCA                      | <1.0    | <3.5 U/ml         |
| anti-SS-A/Ro antibody         | <1.0    | <10.0 U/ml        |
| anti-SS-B/La antibody         | <1.0    | <10.0 U/ml        |
| anti-CCP antibody             | <0.6    | <5 U/ml           |
| Urine test                    |         |                   |
| Leukocyte                     | Negative|                   |
| Nitrite                       | Negative|                   |
| Protein                       | Negative|                   |
| Glucose                       | Negative|                   |
| Urobilinogen                  | Normal  |                   |
| Bilirubin                     | Negative|                   |
| Ketone                        | (3+)    |                   |
| Blood                         | Negative|                   |
| pH                            | 5       |                   |
| Specific gravity              | 1.018   |                   |

**TABLE 1: Initial laboratory data of the patient**

CK - creatine kinase; CRP - C-reactive protein; TSH - thyroid-stimulating hormone; HCV - hepatitis C virus; SARS-CoV-2 - severe acute respiratory syndrome coronavirus 2; HBs - hepatitis B surface antigen; HBc - hepatitis B core antigen; C3 - complement component 3; C4 - complement component 4; MPO-ANCA - myeloperoxidase antibody proteinase 3 antibody; SS - Sjögren's syndrome; CCP - cyclic citrullinated peptide

Contrast-enhanced abdominal computed tomography (CT) revealed multiple diverticula with extraluminal gas in the ascending colon (Figure 1).

**FIGURE 1: Enhanced computed tomography showing multiple diverticula with extra-luminal gas in the ascending colon**
Therefore, diverticulitis or perforation of the diverticulum was suspected. Hence the patient was treated with fasting and tazobactam/piperacillin.

After admission, the patient developed pain in both shoulders and thighs, which exacerbated. Additionally, shoulder synovitis and bursitis were observed on ultrasound. We inferred that these symptoms were caused by RA exacerbation due to secondary failure of tocilizumab and started prednisolone 15 mg/day. We also considered drug-induced lupus caused by isoniazid as another possible cause of the symptoms because the antibodies (homogeneous and speckled) levels were >320 times. The results of the tests for anti-dsDNA, anti-RNP and anti-Sm antibodies were all negative; hence, the anti-histone antibody was suspected to be a specific autoantibody. Given that there were no hematological abnormalities or other dermal or serosal inflammatory findings, her condition did not meet the diagnostic criteria for drug-induced lupus. Moreover, because the T-SPOT® test was negative and the possibility of latent tuberculosis infection was low, isoniazid was discontinued.

The shoulder and thigh pain improved on the fourth day of hospitalization and disappeared on the eighth day. The prednisolone dose was reduced to 10 mg, and 6 mg of MTX was added to her treatment. The patient was discharged on the 15th day of hospitalization. In the outpatient follow-up, prednisolone was gradually tapered, and methotrexate was increased to 12 mg/week.

Discussion
Tocilizumab is an antibody against the IL-6 receptor used when RA symptoms are difficult to control with DMARDs. However, suppressing immunity by suppressing IL-6 can make detecting serious infections or RA exacerbations difficult. In particular, the decrease in CRP levels caused by IL-6 inhibition may delay the detection of RA exacerbations due to secondary failure.

Intestinal perforation when using tocilizumab should be noted among infectious diseases because it can be fatal [5]. Although the mechanism of intestinal perforation by tocilizumab has not been clarified, tocilizumab suppresses Th17 cells, which play an important role in the biological defense against infection through innate and acquired immunity in the intestinal mucosa [6]. Specifically, 10-30% of older people have colon diverticulum and are anatomically vulnerable; therefore, they often have diverticulum perforation while using tocilizumab [7]. In cases of RA refractory to MTX, tocilizumab must be used for disease control [4]. Thus, there is a need for risk assessment of the complications associated with tocilizumab and follow-up of the symptoms related to complications such as diverticulum perforation.

Secondary failure of tocilizumab is detected through precise clinical history and physical examination and is not based on laboratory findings. Approximately 1.5% of patients with RA treated with subcutaneous tocilizumab develop an anti-drug antibody, which causes secondary failure of tocilizumab. When treating EORA with tocilizumab, MTX should be concomitantly used to prevent secondary failure [8,9]. However, older patients often have chest radiography or CT abnormalities, which require them to avoid using MTX [10,11]. For instance, in the reported case, the local stricture of the bilateral lungs prevented the use of MTX. There is negative evidence regarding the exacerbation of interstitial pneumonia with low doses of MTX, although this evidence is inconclusive [10,11]. However, given tocilizumab can cause various complications, RA should be treated with MTX when patients have no clear interstitial shadow or an increase in KL-6.

Considering the possibility of secondary failure and complications associated with serious infections is necessary when tocilizumab is used. In this case, the patient had indefinite complaints such as chest tightness, dizziness, and abdominal fullness. Based on the patient’s clinical course, we suspected diverticulitis and perforation of the diverticulum and treated the patient with antibacterial agents. We considered the possibility of secondary failure of tocilizumab because of the general muscular and joint pain and tenderness. Therefore, tocilizumab was discontinued, and treatment with prednisolone and MTX was initiated, which proved effective. Secondary failure can be rare but happen without the usage of MTX, so the possibility should be considered in the treatment of EORA.

Medications can cause various side effects, such as joint pain, and can facilitate the production of autoantibodies, making it difficult to distinguish these side effects from collagen diseases. In this case, isoniazid was suspected as a possible cause because joint pain manifestation was similar to drug-induced lupus. In the tocilizumab treatment course, latent tuberculosis infection (LTBI) is a feared infectious disease. Treatment intervention is recommended for LTBI patients taking prednisolone or immunosuppressants because of the increased risk of active tuberculosis [12]. Although isoniazid is included in the treatment regimen for LTBI, it has a moderate risk of drug-induced lupus erythematosus (DILE). The mechanism of DILE is unknown, but symptoms such as joint pain, muscle aches, fever, serositis, and rash generally appear within a few months to a few years of drug administration [13]. Typically, the results for anti-nuclear and anti-histone antibodies are positive, and those for specific antibodies (anti-Ds-DNA and anti-Sm antibodies) are negative. In our case, isoniazid was not used to activate the LTBI. Since the results for all the specific antibodies were negative, the anti-histone antibody was speculated to be an anti-nuclear antibody. This suggested the possibility of drug-induced lupus caused by isoniazid. Thus, after confirming that the T-SPOT® test was negative, isoniazid was discontinued.
When older patients with RA complain of general pain and arthralgia, it is necessary to consider various possibilities, such as RA exacerbation, secondary failure, or other complications. However, it is difficult to distinguish between these conditions because they have similar clinical symptoms in older patients. Moreover, older patients tend to have vague symptoms, leading to different and incorrect help-seeking behaviors, which can exacerbate their symptoms \([14,15]\). As a result, medical professionals deal with their symptoms in a mild and undeferential manner, with symptomatic treatment affected by ageism \([16,17]\). In particular, various symptoms often appear because of autoimmune diseases in older patients \([18,19]\). Therefore, we strongly suggest considering various possibilities of RA when symptoms of older patients with RA worsen; to this end, health care professionals should take accurate clinical histories, perform precise physical examinations, and follow up with the patients closely.

Conclusions

Here, we report a case of EORA with possible secondary failure of tocilizumab in a community hospital. The characteristics of tocilizumab, the patient’s age, and various medicines used to prevent complications complicated this case. Since tocilizumab can cause various complications and secondary failure, clinicians should take precise clinical histories, perform thorough physical examinations, and use MTX appropriately by considering the risk of interstitial pneumonia. Furthermore, medical professionals should deal with older patients’ symptoms without ageism, especially in patients with autoimmune diseases.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Farrugia M, Baron B: The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells . J Clin Transl Res. 2016, 2:94-90. 10.1085/jctres.02.201603.005
2. Ogata A, Kato Y, Higa S, Yoshizaki K: IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019, 29:258-67. 10.1007/s11305-018-1546-5
3. Dennison EM, Cooper C: Corticosteroids in rheumatoid arthritis. BMJ. 1998, 316:789-90. 10.1136/bmj.316.7534.789
4. Smolen JS, Landewe RB, Bijlsma JW, et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:665-99. 10.1136/annrheumdis-2019-216655
5. Rempenault C, Lukas C, Combe B, et al.: Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology. 2022, 61:953-62. 10.1093/rheumatology/keab438
6. Caron B, Jouzeau JY, Miossec P, Petitpain N, Gillet P, Netter P, Peyrin-Biroulet L: Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opin Drug Saf. 2022, 21:225-39. 10.1080/14740335.2021.1960981
7. Swanson SM, Strate LL: Acute colonic diverticulitis. Ann Intern Med. 2018, 168:65-80. 10.7326/M20180510
8. Ito S, Ishikawa H: Two cases of rheumatoid arthritis for which switching from tocilizumab to sarilumab . Clin Rheumatol Rel Res. 2021, 33:329-37. 10.1097/acr.33.329
9. Salvarani C, Dolci G, Massari M, et al.: Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021, 181:24-31. 10.1001/jamaonalem.2020.6615
10. Sparks JA, Dellaripa PF, Glynn RJ, Paynter NP, Xu C, Riddler PM, Solomon DH: Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial. Arthritis Rheumatol. 2020, 72:2065-71. 10.1002/art.41452
11. Fragoulis GE, Nikiforou E, Larsen J, Korsten P, Conway R: Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med. 2019, 6:238. 10.3389/fmed.2019.00238
12. Iannone F, Cantini F, Lapadula G: Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl. 2014, 91:41-6. 10.3899/jrheum.140101
13. Cerqueira A, Seco T, Paiva D, Martins H, Cotter J: Isoniazid-induced lupus: when the cure can be lethal. Cureus. 2020, 12:e7511. 10.7759/cureus.7511
14. Ohta R, Ryo Y, Sano C: Older people’s help-seeking behaviors in rural contexts: a systematic review. Int J Environ Res Public Health. 2022, 19:2233. 10.3390/ijerph19062233
15. Iannone F, Ryo Y, Kitayuguchi J, Maeno T, Sano C: What resources do elderly people choose for managing their symptoms? Clarification of rural older people's choices of help-seeking behaviors in Japan. BMC Health Serv Res. 2021, 21:640. 10.1186/s12913-021-06684-x
16. Amano S, Ohta R, Sano C: Recognition of anemia in elderly people in a rural community hospital . Int J...
17. Horinishi Y, Shimizu K, Sano C, Ohta R: surgical interventions in cases of esophageal hiatal hernias among older Japanese adults: a systematic review. Medicina. 2022, 58:279. 10.3390/medicina58020279

18. Tokonami A, Ohta R, Tanaka Y, Amano S, Sano C: Pericarditis with cardiac tamponade mimicking yellow nail syndrome in a patient with rheumatoid arthritis and a paucity of joint symptoms. Cureus. 2022, 14:e21523. 10.7759/cureus.21523

19. Ohta R, Okayasu T, Katagiri N, Yamane T, Obata M, Sano C: Giant cell arteritis mimicking polymyalgia rheumatica: a challenging diagnosis. Cureus. 2022, 14:e27517. 10.7759/cureus.27517